Table 1.
Clinical trials previously reviewed by the Huntington’s Disease Clinical Trials Corner. aIONIS-HTTRx, RG6042, and tominersen refer to the same molecule. bVX15/2503 and pepinemab refer to the same molecule. cAAVrh10.CAG.hCYP46A1, BV-101, AB-1001 refer to the same molecule
| Trial name | Intervention | Edition | |
| NCT02519036 | IONIS-HTTRx | IONIS-HTTRxa | September 2017 [6] |
| NCT02215616 | LEGATO-HD | Laquinimod | |
| NCT02197130 | Amaryllis | PF-02545920 | |
| NCT02006472 | PRIDE-HD | Pridopidine | |
| NCT03225833 | PRECISION-HD1 | WVE-120101 | February 2018 [18] |
| NCT03225846 | PRECISION-HD2 | WVE-120102 | |
| NCT01795859 | FIRST-HD | Deutetrabenazine | |
| NCT02481674 | SIGNAL | VX15/2503 | August 2018 [19] |
| NCT00712426 | CREST-E | Creatine | |
| NCT03761849 | GENERATION-HD1 | RG6042a | January 2019 [20] |
| NCT03344601 | PACE-HD | Physical activity | |
| NCT02535884 | HD-DBS | Deep brain stimulation | June 2019 [21] |
| NCT02453061 | TRIHEP3 | Triheptanoin | |
| NCT04120493 | AMT-130 | AAV5-miHTT | April 2020 [22] |
| NCT04102579 | KINECT-HD | Valbenazine | |
| NCT05111249 | VIBRANT-HD | Branaplam | April 2022 [23] |
| NCT04514367 | ANX005 | ANX-005 | |
| NCT04514367 | SHIELD HD | Observational study | |
| NCT03761849 | GENERATION-HD1 | Tominersena | |
| NCT05032196 | SELECT-HD | WVE-003 | |
| NCT03225833 | PRECISION-HD1 | WVE-120101 | |
| NCT03225846 | PRECISION-HD2 | WVE-120102 | |
| NCT02481674 | SIGNAL | Pepinemabb | November 2022 [14] |
| NCT05358717 | PIVOT HD | PTC518 | |
| NCT05686551 | GENERATION HD2 | Tominersena | August 2023 [24] |
| NCT05541627 | AB-1001 | AAVrh10.CAG.hCYP46A1c | |
| NCT05822908 | VO659-CT01 | VO659 | February 2024 |
| NCT05111249 | VIBRANT-HD | Branaplam |